{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T09:42:33Z","timestamp":1780652553949,"version":"3.54.1"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,3]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>This review discusses the findings of recently published translational research studies that have the potential to directly impact on the management of gout patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Recent research suggests that treat-to-target urate-lowering treatment (ULT) alongside individualized education about gout, and shared decision making results in excellent adherence with ULT and prevents gout flares in the long term. Such interventions should preferentially be delivered face-to-face rather than remotely. The recently published CARES study raises the possibility that febuxostat increases the risk of death in people with preexisting major cardiovascular diseases, and, allopurinol should remain the first-choice ULT. There is paucity of data on the dosing of ULT for managing hyperuricaemia in gout patients with chronic kidney disease. However, recent research suggests that the dose of allopurinol can be gradually increased to above the conventional renal dose in people with chronic kidney disease without allopurinol hypersensitivity syndrome. However, additional larger studies are needed in this field.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>In summary, long-term treat-to-target ULT prevents gout flares and improves quality of life. Given the recent safety concerns, gradually up-titrated allopurinol remains the first-line urate-lowering drug.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000000689","type":"journal-article","created":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T11:26:49Z","timestamp":1576495609000},"page":"134-139","source":"Crossref","is-referenced-by-count":4,"title":["Debates in gout management"],"prefix":"10.1097","volume":"32","author":[{"given":"Abhishek","family":"Abhishek","sequence":"first","affiliation":[{"name":"Academic Rheumatology, School of Medicine, University of Nottingham, Nottingham City Hospital"},{"name":"Nottingham National Institute of Health Research Biomedical Research Centre, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230828","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1002\/art.40807","article-title":"Contemporary prevalence of gout and hyperuricemia in the United States and decadal trends: the National Health and Nutrition Examination Survey","volume":"71","author":"Chen-Xu","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"R2-20230828","doi-asserted-by":"crossref","first-page":"58","DOI":"10.7326\/M16-0570","article-title":"Management of acute and recurrent gout: a clinical practice guideline from the American College of Physicians","volume":"166","author":"Qaseem","year":"2017","journal-title":"Ann Intern Med"},{"key":"R3-20230828","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","article-title":"2016 updated EULAR evidence-based recommendations for the management of gout","volume":"76","author":"Richette","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R4-20230828","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.21772","article-title":"2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res"},{"key":"R5-20230828","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","article-title":"Cardiovascular safety of febuxostat or allopurinol in patients with gout","volume":"378","author":"White","year":"2018","journal-title":"N Engl J Med"},{"key":"R6-20230828","doi-asserted-by":"crossref","first-page":"e005354","DOI":"10.1136\/bmjopen-2014-005354","article-title":"Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia","volume":"4","author":"MacDonald","year":"2014","journal-title":"BMJ Open"},{"key":"R7-20230828","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0002-9343(84)90743-5","article-title":"Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency","volume":"76","author":"Hande","year":"1984","journal-title":"Am J Med"},{"key":"R8-20230828","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1136\/annrheumdis-2017-212288","article-title":"Relationship between serum urate concentration and clinically evident incident gout: an individual participant data analysis","volume":"77","author":"Dalbeth","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R9-20230828","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.1002\/art.30649","article-title":"A two-stage approach to the treatment of hyperuricemia in gout: the \u2018dirty dish\u2019 hypothesis","volume":"63","author":"Perez-Ruiz","year":"2011","journal-title":"Arthritis Rheum"},{"key":"R10-20230828","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S0140-6736(18)32158-5","article-title":"Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial","volume":"392","author":"Doherty","year":"2018","journal-title":"Lancet"},{"key":"R11-20230828","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/kez333","article-title":"Nurse-led care is preferred over GP-led care of gout and improves gout outcomes: results of Nottingham Gout Treatment Trial follow-up study","author":"Fuller","year":"2019","journal-title":"Rheumatology (Oxford, England)"},{"key":"R12-20230828","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.semarthrit.2018.02.009","article-title":"Serum urate as surrogate endpoint for flares in people with gout: a systematic review and meta-regression analysis","volume":"48","author":"Stamp","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"R13-20230828","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.semarthrit.2017.09.007","article-title":"Medication adherence among patients with gout: a systematic review and meta-analysis","volume":"47","author":"Scheepers","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"R14-20230828","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jbspin.2018.10.008","article-title":"Implication of nurse intervention on engagement with urate-lowering drugs: a qualitative study of participants in a RCT of nurse led care","volume":"86","author":"Latif","year":"2019","journal-title":"Joint Bone Spine"},{"key":"R15-20230828","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.amjmed.2018.11.011","article-title":"Adherence and outcomes with urate-lowering therapy: a site-randomized trial","volume":"132","author":"Mikuls","year":"2019","journal-title":"Am J Med"},{"key":"R16-20230828","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1136\/annrheumdis-2017-211574","article-title":"Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre randomised study","volume":"77","author":"Yamanaka","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R17-20230828","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s12872-018-0881-6","article-title":"A meta-analysis of the efficacy of allopurinol in reducing the incidence of myocardial infarction following coronary artery bypass grafting","volume":"18","author":"Singh","year":"2018","journal-title":"BMC Cardiovasc Disord"},{"key":"R18-20230828","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1002\/art.40583","article-title":"New perspectives in rheumatology: implications of the cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular morbidities trial and the associated Food and Drug Administration public safety alert","volume":"70","author":"Choi","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"R19-20230828","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1161\/CIRCULATIONAHA.118.033992","article-title":"Assessment of cardiovascular risk in older patients with gout initiating febuxostat versus allopurinol","volume":"138","author":"Zhang","year":"2018","journal-title":"Circulation"},{"key":"R20-20230828","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.jacc.2017.12.052","article-title":"Cardiovascular risks of probenecid versus allopurinol in older patients with gout","volume":"71","author":"Kim","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"R21-20230828","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1002\/art.40486","article-title":"Allopurinol dose escalation and mortality among patients with gout: a national propensity-matched cohort study","volume":"70","author":"Coburn","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"R22-20230828","doi-asserted-by":"crossref","first-page":"e013774","DOI":"10.1136\/bmjopen-2016-013774","article-title":"Multicentre, prospective, randomised, open-label, blinded end point trial of the efficacy of allopurinol therapy in improving cardiovascular outcomes in patients with ischaemic heart disease: protocol of the ALL-HEART study","volume":"6","author":"Mackenzie","year":"2016","journal-title":"BMJ Open"},{"key":"R23-20230828","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s13075-018-1593-0","article-title":"Efficacy and safety of febuxostat extended release and immediate release in patients with gout and moderate renal impairment: phase II placebo-controlled study","volume":"20","author":"Gunawardhana","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"R24-20230828","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/s13075-018-1755-0","article-title":"How much allopurinol does it take to get to target urate? Comparison of actual dose with creatinine clearance-based dose","volume":"20","author":"Stamp","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"R25-20230828","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1136\/annrheumdis-2017-211873","article-title":"Allopurinol dose escalation to achieve serum urate below 6\u200amg\/dL: an open-label extension study","volume":"76","author":"Stamp","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R26-20230828","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1136\/annrheumdis-2016-210872","article-title":"A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout","volume":"76","author":"Stamp","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R27-20230828","doi-asserted-by":"crossref","first-page":"e1002725","DOI":"10.1371\/journal.pmed.1002725","article-title":"No causal effects of serum urate levels on the risk of chronic kidney disease: a Mendelian randomization study","volume":"16","author":"Jordan","year":"2019","journal-title":"PLoS Med"},{"key":"R28-20230828","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1001\/jamainternmed.2018.4463","article-title":"Association of chronic kidney disease with allopurinol use in gout treatment","volume":"178","author":"Vargas-Santos","year":"2018","journal-title":"JAMA Intern Med"},{"key":"R29-20230828","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1186\/s13075-018-1746-1","article-title":"Risk of chronic kidney disease in patients with gout and the impact of urate lowering therapy: a population-based cohort study","volume":"20","author":"Roughley","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"R30-20230828","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s10157-018-1652-5","article-title":"The urate-lowering efficacy and safety of febuxostat versus allopurinol in Chinese patients with asymptomatic hyperuricemia and with chronic kidney disease stages 3-5","volume":"23","author":"Liu","year":"2019","journal-title":"Clin Exp Nephrol"},{"key":"R31-20230828","doi-asserted-by":"crossref","first-page":"e0161","DOI":"10.1097\/MD.0000000000010161","article-title":"Efficacy of febuxostat in hyperuricemic patients with mild-to-moderate chronic kidney disease: a meta-analysis of randomized clinical trials\u2013 a PRISMA-compliant article","volume":"97","author":"Zeng","year":"2018","journal-title":"Medicine"},{"key":"R32-20230828","doi-asserted-by":"crossref","first-page":"e16311","DOI":"10.1097\/MD.0000000000016311","article-title":"Effects of febuxostat on renal function in patients with chronic kidney disease: a systematic review and meta-analysis","volume":"98","author":"Lin","year":"2019","journal-title":"Medicine"},{"key":"R33-20230828","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.psychres.2018.10.067","article-title":"Gout and the risk of incident depression in older adults","volume":"270","author":"Singh","year":"2018","journal-title":"Psychiatry Res"},{"key":"R34-20230828","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1186\/s12877-018-0975-0","article-title":"Gout and dementia in the elderly: a cohort study of Medicare claims","volume":"18","author":"Singh","year":"2018","journal-title":"BMC Geriatr"},{"key":"R35-20230828","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1136\/annrheumdis-2016-210767","article-title":"Uric acid and incident dementia over 12 years of follow-up: a population-based cohort study","volume":"77","author":"Latourte","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R36-20230828","first-page":"1243","article-title":"Use of urate-lowering therapies is not associated with an increase in the risk of incident dementia in older adults","volume":"77","author":"Singh","year":"2018","journal-title":"Ann Rheum Dise"},{"key":"R37-20230828","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11357-016-9871-8","article-title":"Serum uric acid level and association with cognitive impairment and dementia: systematic review and meta-analysis","volume":"38","author":"Khan","year":"2016","journal-title":"Age (Dordr)"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000689","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T05:15:49Z","timestamp":1693199749000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000689"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000689","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3]]}}}